EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
Large epidemiological trails shown that hypercholesterolemia is one of the main risk factor of ischemic heart disease (IHD). Correction of the hypercholesterolemia with GmGKoA reductase inhibitors (statins) essentially reduces IHD morbidity and mortality. The lower serum level of low density lipopro...
Saved in:
| Main Author: | A. N. Meshkov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01) -
Efficacy of atorvastatin therapy in prevention of postoperative atrial fibrillation in patients with ischemic heart disease
by: O. A. Rubanenko
Published: (2015-11-01) -
THE USE OF ATORVASTATIN FOR THE PREVENTION OF RECURRENT ATRIAL FIBRILLATION AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: S. N. Tereshchenko, et al.
Published: (2016-01-01) -
ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING
by: A. V. Panov, et al.
Published: (2017-07-01) -
EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01)